## Sexual Dysfunction and SSRIs **Key Point:** Paroxetine has the highest incidence of sexual dysfunction among all SSRIs, affecting 40–60% of patients, making it the most problematic agent in this class. ### Mechanism of Sexual Dysfunction in SSRIs SSRIs cause sexual dysfunction through increased serotonergic activity in the hypothalamus and spinal cord, which: 1. Inhibits dopamine release (dopamine normally facilitates sexual arousal) 2. Increases prolactin levels (prolactin antagonizes sexual function) 3. Suppresses nitric oxide production in penile tissue (impairs erectile function) ### Comparative Incidence of Sexual Dysfunction Across SSRIs | SSRI | Incidence of Sexual Dysfunction | Relative Risk | |------|----------------------------------|---------------| | **Paroxetine** | 40–60% | **Highest** | | Fluoxetine | 25–35% | Moderate | | Sertraline | 15–25% | Lower | | Citalopram | 10–20% | Lowest | **High-Yield:** Paroxetine's higher potency for serotonin reuptake inhibition and longer half-life contribute to greater sexual dysfunction. It is also the most anticholinergic among SSRIs, adding to adverse effects. ### Clinical Management Strategies - **Dose reduction** — may improve sexual function while maintaining antidepressant efficacy - **Drug switching** — to sertraline or citalopram (lower incidence) - **Augmentation** — bupropion (dopamine agonist) or buspirone can counteract sexual dysfunction - **Drug-free interval** — brief washout periods (not recommended due to relapse risk) **Clinical Pearl:** In patients with depression and baseline sexual dysfunction concerns, sertraline or citalopram are preferred first-line SSRIs. Paroxetine is reserved for specific indications (panic disorder, social anxiety) where its side effect profile is accepted. **Warning:** Do NOT switch SSRIs abruptly in patients reporting sexual dysfunction — taper and transition gradually to avoid withdrawal syndrome.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.